The Neuroendocrine Tumor Research Foundation (NETRF), in partnership with the North American Neuroendocrine Tumor Society (NANETS), is proud to announce Victor Santoro Fernandes, PhD, as
The University of Pennsylvania is now enrolling patients in the new phase 1/2 multi-center clinical trial for CAR T cell therapy. The trial includes patients
NETRF is pleased to announce that Daniel Halperin, MD, one of our distinguished Board of Scientific Advisors members, has been appointed Vice Chair of Clinical
NETRF congratulates Dr. Michael Roehrl on his research progress and recent publication. NETRF’s recent Investigator Award to Michael Roehrl, MD, PhD, MBA, Chief of Pathology at…
The Neuroendocrine Tumor Research Foundation (NETRF) extends its deepest gratitude to Ramesh Shivdasani, MD, PhD (Dana-Farber Cancer Institute), George Fisher, MD, PhD (Stanford University), and Daniel Chung, MD (Massachusetts General Hospital) for their exceptional service as members and former Chairs of the NETRF Board of Scientific Advisors (BOSA).
Welcome to the latest research highlights from the Neuroendocrine Tumor Research Foundation (NETRF). In this blog post, we dive into two new research studies funded
The results of a phase 2 clinical trial, the Natalie Trial, suggest that the drug cabozantinib may hold promise as a therapeutic option for some
One of the main challenges in neuroendocrine tumor (NET) research is the scarcity of models that accurately represent the disease. These models are essential for
NETRF-funded researchers have recently reported in the journal GigaScience the first multi-omic dataset of patient-derived tumor organoids of neuroendocrine neoplasms (NENs). This includes large cell
At NETRF, our mission is to fund research that holds promise for advancing the understanding and treatment of neuroendocrine neoplasms (NENs). This is a commitment